Dapagliflozin effects on haematocrit, red blood cell count and reticulocytes in insulin-treated patients with type 2 diabetes

Aberle, Jens; Menzen, Markus; Schmid, Sebastian M.; Terkamp, Christoph; Jaeckel, Elmar; Rohwedder, Katja; Scheerer, Markus F.; Xu, John; Tang, Weifeng; Birkenfeld, Andreas L.

dc.contributor.author	Birkenfeld, Andreas L.
dc.date.accessioned	2021-07-13T06:28:48Z
dc.date.available	2021-07-13T06:28:48Z
dc.date.issued	2020
dc.identifier.issn	2045-2322
dc.identifier.uri	http://hdl.handle.net/10900/117073
dc.language.iso	en	de_DE
dc.publisher	Nature Research	de_DE
dc.relation.uri	http://dx.doi.org/10.1038/s41598-020-78734-z	de_DE
dc.subject.ddc	500	de_DE
dc.title	Dapagliflozin effects on haematocrit, red blood cell count and reticulocytes in insulin-treated patients with type 2 diabetes	de_DE
dc.type	Article	de_DE
utue.quellen.id	20210304112512_00027
utue.personen.roh	Aberle, Jens
utue.personen.roh	Menzen, Markus
utue.personen.roh	Schmid, Sebastian M.
utue.personen.roh	Terkamp, Christoph
utue.personen.roh	Jaeckel, Elmar
utue.personen.roh	Rohwedder, Katja
utue.personen.roh	Scheerer, Markus F.
utue.personen.roh	Xu, John
utue.personen.roh	Tang, Weifeng
utue.personen.roh	Birkenfeld, Andreas L.
dcterms.isPartOf.ZSTitelID	Scientific Reports	de_DE
dcterms.isPartOf.ZS-Issue	Article 22396	de_DE
dcterms.isPartOf.ZS-Volume	10	de_DE
utue.fakultaet	04 Medizinische Fakultät	de_DE